| Autor: |
Marko Lucijanic, Bušić, N., Bistrović, P., Papić, I., Zelenika Margeta, M., Babić, P., Barčan, M., Pasarić, A., Mustapić, M., Piskač Živković, N., Ortner Hadžiabdić, M., Lucijanić, T., Lukšić, I., Baršić, B. |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Scopus-Elsevier |
| ISSN: |
1332-8166 |
| Popis: |
Aim: To evaluate the association of remdesivir use and the survival of hospitalized patients with coronavirus disease 2019 (COVID-19). ----- Methods: We retrospectively reviewed the medical records of 5959 COVID-19 patients admitted to our tertiary-level hospital from March 2020 to June 2021. A total of 876 remdesivir-treated patients were matched with 876 control patients in terms of age, sex, Charlson comorbidity index (CCI), WHO-defined COVID-19 severity on admission, and oxygen requirement at the time of remdesivir use. ----- Results: Among 1752 COVID-19 patients (median age 66 years, 61.8% men), 1405 (80.2%) had severe and 311 (17.8%) had critically severe COVID-19 on admission. Remdesivir was given at a median of one day after hospital admission and at a median of eight days from the onset of symptoms. Overall, 645 (73.6%) patients received remdesivir before high-flow oxygen therapy (HFOT) or mechanical ventilation (MV), 198 (22.6%) after HFOT institution, and 83 (9.5%) after MV institution. Remdesivir use was associated with improved survival in the entire cohort (hazard ratio 0.79, P=0.006). Survival benefit was evident among patients receiving remdesivir during low-flow oxygen requirement (hazard ratio 0.61, P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
